CPU 86017 suppresses tachyarrhythmias induced by ouabain and myocardial infarction: Concentrations in plasma and different areas of the heart in dogs

Drug Development Research

Volumn 58, Issue 1, 2003, Pages 131-137

  Cui, Yu Jin ^a   Yang, Ping ^a   Dai, De Zai ^a   Gao, Ling ^a   Xiao, Da Wei ^b   Wang, You Qun ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

^b First Municipal Hospital of Nanjing   (China)

Author keywords

Antiarrhythmic agents; CPU 86017; Heart; Myocardial infarction; Ouabain; Pharmacodynamics; Pharmacokinetics

Indexed keywords

4 CHLOROBENZYLTETRAHYDROBERBERINE; AMIODARONE; BERBERINE DERIVATIVE; CPU 86017; OUABAIN; UNCLASSIFIED DRUG;

ADIPOSE TISSUE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIARRHYTHMIC ACTIVITY; CONFERENCE PAPER; CONTROLLED STUDY; CORONARY ARTERY LIGATION; DOG; DOSE RESPONSE; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG LIVER LEVEL; DRUG MEGADOSE; FEMALE; HEART ARREST; HEART ATRIOVENTRICULAR NODE; HEART BLOCK; HEART INFARCTION; HEART MUSCLE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HYSTERESIS; KIDNEY; MALE; NONHUMAN; QT INTERVAL; SINUS NODE; SINUS RHYTHM; SKELETAL MUSCLE; TACHYCARDIA; TORSADE DES POINTES;

EID: 0037282593     PISSN: 02724391     EISSN: None     Source Type: Journal    
DOI: 10.1002/ddr.10142     Document Type: Conference Paper

References (14)

1. Anyukhovsky EP, Sosunov EA, Feinmark SJ, Rosen MR. 1997. Effects of quinidine on repolarization in canine epicardium, mid myocardium, and endocardium II. In vivo study. Circulation 96:4019-4026.
2. Bril A, Forest MC, Cheval B, Faivre JF. 1998. Combined potassium and calcium channel antagonistic activities as a basis for neutral frequency dependent increase in action potential duration: comparison between BRL-32872 and Azimilide. Cardiovas Res 37:130-140.
3. Chen JG, Xue YX, Eto K, Ni C, Hashimoto K. 1996. Effects of Dofetilide, a class III antiarrhythmic drug, on various ventricular arrhythmias in dogs. J Cardiovasc Pharmacol 28:576-584.
4. Dai DZ. 2000. Vulnerable substrate and multiple ion channel disorder in a diseased heart will be new targets for antiarrhythmic therapy. Acta Pharmacol Sin 21:289-295.
5. Dai DZ. 2001. Disorder of ion channels and development of antiarrhythmic agents. Pharmaceut News 8:52-57.
6. Dai DZ, Yu F, Li HT, Tang YQ, An LF, Huang WL, Peng SX, Hao XM, Zhou BA, Wu CH. 1996. Blockade on sodium, potassium and calcium channels by a new antiarrhythmic agent CPU 86107. Drug Dev Res 39:138-146.
7. Finance O, Manning A, Chatelain P. 1995. Effects of a new amiodarone-like agent. SR 33589, in comparison to amiodarone, DL-sotalol, and lignocaine on ischemic-induced ventricular arrhythmias in anesthetized pigs. J Cardiovasc Pharmacol 26:570-576.
8. Gill J, Heel RC, Fitton A. 1992. Amiodarone, An overview of its pharmacological properties, and review of its therapeutic use in cardiac arrhythmias. Drugs 43:69-110.
9. Gillis AM, Mathison HJ, Kulisz E, Laster WM. 2000. Dispersion of ventricular repolarization and ventricular fibrillation in left ventricular hypertrophy: influence of selective potassium channel blockers. J Pharmacol Exp Ther 292:381-386.
10. Guerra PG, Talajic M, Roy D, Dubuc M, Thibault B, Nattel S. 1998. Is there a furture for antiarrhythmic drug therapy? Drugs 56:767-81.
11. Li HT, Wang YQ, Dai DZ, Kong RZ. 2001. Frequency dependent prolongation of effective refractory period by a complex class III antiarrhythmic agent CPU 86017. Acta Pharmacol Sin 22:2-36.
12. Ma YP, Hao XM, Zhang GQ, Zhou PA, Wu CH. Dai DZ. 2000. Blocking effect of CPU 86017 on the slow activated rectifier potassium current in single ventricular myocytes of guinea pigs. J Chin Pharmaceut Univ 312 121-125.
13. Marban E. 2002. Cardiac channelopathies. Nature; 415:213-218.
14. Wang YQ, Su L, Gong GQ, Liu JH. 1994. Guanfu base A inhibit the post-infarction ventricular arrhythmias in dogs. Yao Xue Xue Bao 1994;29:141-144.